Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
Relief Therapeutics will issue 1 billion new shares from its authorized capital around July 27, 2021, as part of a strategic transformation into a diversified commercial-stage pharmaceutical company. Approximately 140 million shares will be used for the acquisition of AdVita, and about 206.8 million shares for APR. The remaining shares are reserved for future financing and corporate purposes. The acquisitions bolster Relief's pipeline, particularly its lead candidate, RLF-100, targeting respiratory deficiency due to COVID-19.
- Transformational acquisitions of AdVita and APR diversify Relief's product pipeline.
- RLF-100 advances in late-stage clinical testing for COVID-19 treatment.
- The issuance of 1 billion new shares may dilute existing shareholder value.
Shares being used in part for payments related to AdVita and APR acquisitions
Acquisitions are part of Relief's transformation into a fully integrated diversified commercial-stage pharmaceutical company
GENEVA, SWITZERLAND / ACCESSWIRE / July 22, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the Company will, on or around July 27, 2021, issue 1,000,000,000 additional registered shares out of the authorized share capital approved by the Annual General Meeting on June 18, 2021. The new shares are fully subscribed at par value by the Company's wholly owned subsidiary, Relief Therapeutics International SA, and will be listed on the SIX Swiss Exchange on or around July 28, 2021. Some of the shares will be used for contractually agreed payments to the respective sellers of AdVita Lifescience GmbH ("AdVita") and APR Applied Pharma Research SA ("APR"): approximately 140,000,000[1] shares and 206,786,784 shares, respectively. The remaining new shares will be held as treasury shares for possible future financing transactions, acquisitions, general corporate purposes, and the settlement of possible future contingent milestone payments to the APR and AdVita sellers. The APR sellers are generally subject to a 75-day lock-up period and a subsequent leak-out schedule.
Jack Weinstein, CFO and Treasurer of Relief, said: "During the course of 2021, we have taken several important steps to transform Relief into a multi-product, revenue-generating company. One critical component of that was the recently closed acquisition of APR, which brings us a diverse pipeline, including market-stage products, and provides a commercial springboard for future Relief product launches. We also are strengthening our intellectual property position with our lead candidate, RLF-100(TM) (aviptadil), through the planned acquisition of AdVita. We are also actively continuing to look for other opportunities as we build our business."
The associated listing prospectus will be listed on the SIX Prospectus Office's website and will be made available upon request once it has been approved by the SIX Swiss Exchange, which is expected on or around July 27, 2021.
###
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's acquisition of APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
Mail: contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG
Anne Hennecke
Tel.: +49 (0) 211-529-252-22
Mail: relief@mc-services.eu
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
[1] The exact figure is i.a. dependent on Relief's closing share price on the SIX trading day preceding the closing date of Relief's acquisition of AdVita's outstanding shares.
SOURCE: Relief Therapeutics Holdings AG
View source version on accesswire.com:
https://www.accesswire.com/656612/Relief-Announces-Issuance-of-Shares-from-Authorized-Capital-as-Approved-by-2021-Annual-General-Meeting
FAQ
What is the purpose of the new shares issued by RLFTF?
When will Relief Therapeutics issue the new shares for RLFTF?
How many shares are associated with the acquisition of AdVita by RLFTF?
What does the acquisition of APR bring to RLFTF?
What is Relief Therapeutics' lead drug candidate?
